Afgelopen week was er in Madrid ESMO 2023. Hier een aantal aanbevolen abstracten door vooraanstaande oncologen gerelateerd aan blaaskanker, urineleiderkanker en nierkanker.

De aanbevolen abstracten staan onder elkaar in dit artikel. Als u naar ESMO 2023 gaat kunt u via de nummers vooraf aan de titels van de abstracten deze vinden.

Recommendations From Dr. Guru Sonpavde for Bladder Cancer

Saturday, October 21, 2023
8:30–9:50 CEST; Proffered Paper Session 1
Genitourinary Tumours, Non-Prostate

LBA102 THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment. JW Catto

Take-Home Message

ERDA prolonged recurrence-free survival compared with chemo in patients with papillary-only high-risk NMIBC with FGFRalt who had recurrence after BCG treatment.
ERDA toxicity was generally consistent with the known safety profile of oral FGFR inhibitors.

2359O Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt). AO Siefker-Radtke

Take-Home Message

Overall survival was similar between ERDA and pembrolizumab in this anti–PD-L1 naïve, FGFRalt metastatic urothelial cancer population, with ERDA showing a numerically longer progression-free survival and numerically higher objective response rate.
Toxicities were manageable with dose modifications.

2360O The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as ≥ second-line therapy for metastatic urothelial carcinoma (mUC). BA McGregor

Take-Home Message

Sacituzumab govitecan plus enfortumab vedotin was safe, with an objective response rate of 71% in patients with treatment-refractory urothelial carcinoma.
Further double antibody–drug conjugate expansion cohorts in treatment-refractory and naïve settings are in development; triplet therapy with immunotherapy is being explored as a new direction for drug development in this disease.

Sunday, October 22, 2023
10:15–11:45 CEST; Mini Oral Session
Genitourinary Tumours, Non-Prostate

LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt). A Vilaseca

Take-Home Message

TAR-210 appears to be safe and well-tolerated with predominantly low-grade urinary system adverse events and high complete response rates and recurrence-free survival in patients with NMIBC with FGFRalt.
Results justify further study of targeted treatment with ERDA using a novel intravesical delivery system in early-stage bladder cancer.

LBA105 Results from SunRISe-1 in patients (Pts) with bacillus Calmette–Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy. A Necchi

Take-Home Message

In SunRISe-1, TAR-200 monotherapy is associated with an unprecedented complete response rate, durable responses, and a favorable tolerability profile in patients with BCG-unresponsive carcinoma in situ, supporting its continued investigation in high-risk NMIBC.

Sunday, October 22, 2023
16:30–18:15 CEST; Proffered Paper Session
Presidential 2

LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). TB Powles

Take-Home Message

Enfortumab vedotin plus pembrolizumab significantly improved outcomes in patients with previously untreated locally advanced metastatic urothelial carcinoma, nearly doubling the median progression-free and overall survival versus chemo. The safety profile was generally manageable with no new safety signals.
These results support enfortumab vedotin plus pembrolizumab as a new standard of care for locally advanced metastatic urothelial carcinoma.

LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial. MS Van der Heijden

Take-Home Message

Nivolumab plus gemcitabine–cisplatin demonstrated statistically significant and clinically meaningful improvements in overall and progression-free survival versus gemcitabine–cisplatin alone as first-line treatment for metastatic urothelial carcinoma, with no new toxicity signals. Nivolumab plus gemcitabine–cisplatin is the first frontline concurrent checkpoint inhibitor plus chemo combination to improve overall survival in this setting.
These results support nivolumab plus cisplatin-based chemo as a new standard of care for patients with metastatic urothelial carcinoma.

Aanbevolen abstracten van studies bij nierkanker door Dr. Eric Jonasch:

Saturday, October 21, 2023
14:45–16:10 CEST; Proffered Paper Session
Genitourinary Tumours, Non-Prostate

LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC). TK Choueiri

LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study. L Albiges

1881O Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study. N Agarwal

1882O RENOTORCH: Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced renal-cell carcinoma (RCC) - A randomized, open-label, phase III study. X Sheng

Sunday, October 22, 2023
10:15–11:45 CEST; Mini Oral Session
Genitourinary Tumours, Non-Prostate

1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC). MH Voss

1884MO Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study. R Iacovelli

aanbevolen abstracten ESMO 2023, blaaskanker, urineleiderkanker, nierkanker